Integrating in vitro sensitivity and dose-response slope is predictive of clinical response to ABL kinase inhibitors in chronic myeloid leukemia

BCR-ABL mutations result in clinical resistance to ABL tyrosine kinase inhibitors (TKIs) in chronic myeloid leukemia (CML). Although in vitro 50% inhibitory concentration (IC(50)) values for specific mutations have been suggested to guide TKI choice in the clinic, the quantitative relationship betwe...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Vainstein, Vladimir, Eide, Christopher A., O’Hare, Thomas, Shukron, Ofir, Druker, Brian J.
Formato: Artigo
Lenguaje:Inglês
Publicado: American Society of Hematology 2013
Materias:
Myeloid Neoplasia
Acceso en línea:https://ncbi.nlm.nih.gov/pmc/articles/PMC3821725/
https://ncbi.nlm.nih.gov/pubmed/24062017
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/blood-2012-08-452409
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares